Pvg Asset Management Corp Gilead Sciences, Inc. Transaction History

Pvg Asset Management Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 14, 2021	SELL	$60.0 - $68.46 $558,300 - $637,020	-9,305 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$62.63 - $80.22 $22,922 - $29,360	-366 Reduced 3.78%	9,305 $695,000
Q4 2019 Feb 26, 2020	BUY	$61.62 - $67.78 $595,927 - $655,500	9,671 New	9,671 $628,000
Q3 2019 Nov 15, 2019	SELL	$62.51 - $69.0 $898,081 - $991,323	-14,367 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$61.87 - $69.38 $888,886 - $996,782	14,367 New	14,367 $970,000

Q4 2018 Feb 15, 2019	SELL	$60.54 - $79.0 $159,825 - $208,560	-2,640 Closed	0 $0
Q3 2018 Nov 15, 2018	BUY	$71.28 - $78.92 $188,179 - $208,348	2,640 New	2,640 $203,000

1,885

8.71M

8.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $84.9B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Pvg Asset Management Corp, based on Form 13F filings with the SEC.

Stay updated on Pvg Asset Management Corp with notifications on news.